Pharmacological Modulation of Cocaine Effects - 1
Pharmacological Modulation of Cocaine Effects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224 6823
- Johns Hopkins University (BPRU) Bayview Campus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: George Bigelow, Ph.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Psychotropic Drugs
- Antidepressive Agents
- Monoamine Oxidase Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Selegiline
Other Study ID Numbers
Other Study ID Numbers
- NIDA-05196-1
- R01-05196-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine-Related Disorders
-
NCT05857852CompletedCocaine Use Disorder | Cocaine Dependence | Ultrasound | Cocaine Abuse
-
NCT01030692CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
-
NCT01651364CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
-
NCT01601730CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
-
NCT06045793TerminatedCocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
-
NCT01651377CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
-
NCT02563769CompletedCocaine-Related Disorders | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
-
NCT05824221Not yet recruitingCocaine Dependence | Cocaine Use | Cocaine Abuse | Neurotropism
-
NCT01025219Unknown
-
NCT01601743CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine Addiction
Clinical Trials on Selegiline
-
NCT07452692Not yet recruitingMajor Depressive Disorder (MDD)
-
NCT00218517Completed
-
NCT06607744Completed
-
NCT00013585CompletedHIV Infections | Cognition Disorders
-
NCT05938517Completed
-
NCT07571824Active, not recruitingHealthy Adult Participants
-
NCT01912391CompletedBorderline Personality Disorder
-
NCT00027040CompletedHIV Infections | Cognitive Disorders